About Keystone Heart
Keystone Heart is a Healthcare company based in Tampa (United States) founded in 2004, and was acquired by Venus MedTech in September 2018. It operates as an embolic cerebral protection devices. Keystone Heart has raised $14 million across 1 funding round from investors including Venus MedTech and Orbimed. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its competitors include Claret Medical, Emboline, Protembis, Synaptive Medical and Filterlex Medical and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Keystone Heart produces TriGuard, embolic cerebral protection devices to decrease the risk of stroke, neurocognitive decline and dementia caused by brain emboli during cardiovascular procedures such as Surgical valve replacement, Ablation for Atrial fibrillation, TAVR etc... The TriGuard device uses a self deploying and self positioning Nitinol frame and mesh to provide coverage to all three major blood vessels arising from the Aortic arch. TriGuard is not commercially available in USA as of June 2016.
- Headquarters Tampa, United States
- SectorsHealthcare
- Email••••••••
- Website keystoneheart.com
- Social LinkedIn
- Acquired by Venus MedTech (Sep 2018)
- Total Equity Funding$14M (USD)
in 1 rounds
- Latest Funding Round$14M (USD), Series B
May 2014
- InvestorsVenus MedTech
& 1 more
- Acquired byVenus MedTech
(Sep 2018)
Funding Insights of Keystone Heart
Keystone Heart has successfully raised a total of $14M through 1 strategic funding round. The most recent funding activity was a Series B round of $14 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14M
- Total Rounds 1
- Last Round Series B — $14M
- First Round $14M
(May 2014)
- Investors Count 1
All 1 funding rounds of Keystone Heart with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | $14M | Series B | – | – |
2 investors in total: 2 institutional.
Investors in Keystone Heart
Keystone Heart has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Venus MedTech and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Transcatheter aortic and pulmonic valves are developed for cardiovascular procedures. | 2009 | venusmedtech.com | Hangzhou, China |
Investor details for Keystone Heart
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Keystone Heart
3 dated milestones of Keystone Heart across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Keystone Heart is founded.
- Funding First funding round of $14.0M.
- Exit Acquired by Venus MedTech.
Competitors of Keystone Heart
Keystone Heart has 9 listed competitors in our database, 9 of them funded. They include Claret Medical, Emboline, Protembis, Synaptive Medical and Filterlex Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| claretmedical.com | 2009 | Santa Rosa, United States | $47.76M | 105 | Cerebral vascular protection systems for endovascular procedures are developed. | |
| emboline.com | 2011 | Santa Cruz, United States | $81.92M | 16 | Aortic embolic protection devices are developed for cardiovascular procedures. | |
| protembis.com | 2013 | Aachen, Germany | $45.17M | 3 | Manufacturer of cerebral protection device | |
| synaptivemedical.com | 2012 | Toronto, Canada | $76.83M | – | Planning and imaging solutions for neurosurgery are developed. | |
| filterlex.com | 2015 | Tel Aviv, Israel | $16.89M | – | Developer of an embolic protection device | |
| embrella.net | 2007 | Malvern, United States | $6.7M | – | Embolic cerebral protection is enhanced for cardiovascular procedures. | |
| transversemedical.com | 2011 | Golden, United States | $26.77M | – | Developer of a device to prevent stroke during transcatheter aortic valve replacement heart procedures | |
| invictusmed.com | 2010 | San Antonio, United States | $8.93M | – | Pediatric medical devices for infant care are developed and explored. | |
| neuramedica.com | 2014 | Oregon, United States | $1.85M | – | Bioabsorbable dural clips are developed for durotomy and spinal closures. |
Detailed competitors of Keystone Heart
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as Keystone Heart (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Keystone Heart
Complete news archive for Keystone Heart
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Keystone Heart
Keystone Heart was founded in 2004 and raised its 1st funding round 10 years after it was founded.
Keystone Heart is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Keystone Heart is a funded company, having raised a total of $14M across 1 funding round to date. The company's 1st funding round was a Series B of $14M, raised on May 2014.
Keystone Heart produces TriGuard, embolic cerebral protection devices to decrease the risk of stroke, neurocognitive decline and dementia caused by brain emboli during cardiovascular procedures such as Surgical valve replacement, Ablation for Atrial fibrillation, TAVR etc... The TriGuard device uses a self deploying and self positioning Nitinol frame and mesh to provide coverage to all three major blood vessels arising from the Aortic arch. TriGuard is not commercially available in USA as of June 2016.
Keystone Heart's top competitors include Protembis, Synaptive Medical and Emboline.
Keystone Heart has 2 investors. Key investors include Venus MedTech, and Orbimed.
Yes. Keystone Heart was acquired by Venus MedTech in September 2018.